Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > ARCHIVE
ARCHIVE
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
- Pfizer Japan Files Public Knowledge-based Application for Diflucan
June 20, 2011
- US CRO to Provide Financial Support to Codevelopment Partner of MediBIC
June 20, 2011
- Amgen to Focus on 4 Fields Including Cancer Taking Advantage of Its Strength in Biotech
June 20, 2011
- Novartis Files Public Knowledge-based Applications for Add'l Indications for 3 More Products
June 20, 2011
- Takeda Presents PI Data on MLN4924 at ASCO
June 20, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
- Eisai's Achievements Most Conspicuous in FY2011 Settlement of Accounts: Nomura Securities
June 13, 2011
- IMUC Becomes 18th Licensee for POTELLIGENT Technology: BioWa
June 13, 2011
- Kyowa Hakko Bio Establishes Efficient Amino Acid Derivative Manufacturing Process
June 13, 2011
- Teijin: Bonalon, Onealfa Contribute to Growth in Sales
June 13, 2011
- DSP to Inaugurate Global Oncology Business Development Office
June 13, 2011
- NanoCarrier's Micelle Technology Moves Closer to Patent in Japan
June 13, 2011
- Meiji HD: Pharmaceuticals Segment's Sales Up 2.3%
June 13, 2011
- JPMA to Issue Serious Warning against MSD over PC Violations
June 13, 2011
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…